$MEDI - Far More Attractive Than Their Competition Ketamine One ($MEDI) is a hidden gem among the psychedelic sector. They focus on research and development in addition to their extensive clinical network. Let's compare it to some of their competitors here.
- $FTRP $328M: 7 locations in Canada, USA, and Amsterdam.
- $NUMI $171M: 3 locations in Montreal and Vancouver
- $NM $36M: 6 locations in Utah
- $MEDI $161M: 16 clinics across NA
$MEDI has the largest clinical network among all their major competitors. Plus, they not only have a tremendous clinical footprint, but they also have a top-notch cutting-edge research program. The clinical network has helped them gather thousands of data points for clinical research. Through KGK Sciences (and the 24 years of experience), they've been able to generate contracts and revenues ($2.3M to be exact). KGK provides investors with actual results, not any of this pre-clinical molecule nonsense that won't be on the market anytime soon.
So, $MEDI has a leading clinic network across NA, consistent business growth with contracts and new acquisitions, and a leading research team. All of these combined show why $MEDI is a far better choice than many other companies in the psychedelic space. Backing a valuation with real numbers and fundamental growth instead of pure speculation.
Overall, Ketamine One is one to keep an eye on. They continue to grow and develop their business both organically and through acquisitions. The current market cap is $161M.